Cargando…
Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603333/ http://dx.doi.org/10.1186/2052-3211-8-S1-O3 |
| _version_ | 1782394898123587584 |
|---|---|
| author | Lukačišinová, Anna Skácelová, Helena |
| author_facet | Lukačišinová, Anna Skácelová, Helena |
| author_sort | Lukačišinová, Anna |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4603333 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46033332015-10-14 Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure Lukačišinová, Anna Skácelová, Helena J Pharm Policy Pract Oral Presentation BioMed Central 2015-10-05 /pmc/articles/PMC4603333/ http://dx.doi.org/10.1186/2052-3211-8-S1-O3 Text en Copyright © 2015 Lukačišinová and Skácelová http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Lukačišinová, Anna Skácelová, Helena Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title | Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title_full | Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title_fullStr | Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title_full_unstemmed | Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title_short | Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| title_sort | highly innovative drugs in the czech republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603333/ http://dx.doi.org/10.1186/2052-3211-8-S1-O3 |
| work_keys_str_mv | AT lukacisinovaanna highlyinnovativedrugsintheczechrepublicretrospectiveanalysisofimpactonearlymarketentryregularreimbursementsystementryandpublicpharmaceuticalexpenditure AT skacelovahelena highlyinnovativedrugsintheczechrepublicretrospectiveanalysisofimpactonearlymarketentryregularreimbursementsystementryandpublicpharmaceuticalexpenditure |